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Mammalian prions cause lethal neurodegenerative diseases such as Creutz-
feldt–Jakob disease (CJD) and consist of multi-chain assemblies of
misfolded cellular prion protein (PrPC). Ligands that bind to PrPC can inhibit
prion propagation and neurotoxicity. Extensive prior work established that
certain soluble assemblies of the Alzheimer’s disease (AD)-associated amy-
loid b-protein (Ab) can tightly bind to PrPC, and that this interaction may be
relevant to their toxicity in AD. Here, we investigated whether such soluble
Ab assemblies might, conversely, have an inhibitory effect on prion propa-
gation. Using cellular models of prion infection and propagation and distinct
Ab preparations, we found that the form of Ab assemblies which most
avidly bound to PrP in vitro also inhibited prion infection and propagation.
By contrast, forms of Ab which exhibit little or no binding to PrP were
unable to attenuate prion propagation. These data suggest that soluble
aggregates of Ab can compete with prions for binding to PrPC and empha-
size the bidirectional nature of the interplay between Ab and PrPC in
Alzheimer’s and prion diseases. Such inhibitory effects of Ab on prion propa-
gation may contribute to the apparent fall-off in the incidence of sporadic
CJD at advanced age where cerebral Ab deposition is common.
1. Introduction
Prion diseases are fatal neurodegenerative disorders associated with propa-
gation of multi-chain assemblies of misfolded cellular prion protein (PrPC)
[1,2]. Prions propagate by recruitment of a-helical-rich PrPC into b-sheet-rich
infectious rod-like structures [3,4]. In addition to serving as the precursor of
infectious prions, expression of PrPC is also required for the neurotoxicity in
prion infection [5–8].
Numerous studies suggest PrPC may play a role in Alzheimer’s disease
(AD), and there is evidence that PrP can modulate the production, aggregation
and toxicity of the amyloid b-protein (Ab) [9–11]. In 2009, Lauren et al. [11]
reported that a preparation of aggregated synthetic Ab1-42 known as
Ab-derived diffusible ligands (ADDLs), which contained a mixture of globular
oligomers and protofibrils, bound to PrPC. Using a series of deletion constructs
and anti-PrP antibodies, it was shown that PrP residues 95–110 were required
for ADDL binding. In accord with this finding, the authors demonstrated that
knock-out of the mouse PrP gene (Prnp) or pre-treatment of hippocampal slices
with an antibody directed to PrP93-109 protected against ADDL-induced synap-
totoxicity. These provocative findings were followed by multiple in vivo and
in vitro studies, most of which supported a role for PrPC in aspects of Ab-
mediated toxicity [10,12–21]. However, others have reported deleterious effects
of Ab that do not require PrPC expression [22–25]. Recently, we reported that
& 2017 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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only certain Ab assemblies exert toxicity in a PrP-dependent
fashion which may explain some of these apparently discre-
pant findings [26].
However, all published studies that have examined bind-
ing of Ab to PrPC agree that there is high affinity and specific
binding for soluble aggregates [11,13,21–23,26–29], and
high-resolution analysis suggests that binding of Ab occurs
at two sites: centred around residues approximately 23–33
and approximately 88–113 [29]. Although initially surpris-
ing, the finding that PrPC can serve as an acceptor for
soluble aggregates of Ab [11] is consistent with the hypoth-
esis that the unstructured N-terminus (encompassing
residues approx. 23–128) of PrPC acts as a molecular sensor
which can interact with a broad range of ligands [30], includ-
ing other b-sheet-rich oligomeric proteins [28]. Moreover, the
same binding sites for soluble aggregates of Ab have pre-
viously been shown to also be important for binding of
prions to PrPC [31–36].
While many studies have investigated the interaction
between Ab and PrPC, and how it might contribute to AD
pathogenesis, there has been little research on whether Ab
binding to PrPC can affect prion propagation. Here, we
used the well-established cell-based prion bioassay (the scra-
pie cell assay using PK1/2 neuroblastoma-derived cells) [37]
and a chronically prion-infected cell line (iPK1/2 cells) [38,39]
to address these critical issues. We found that soluble Ab
aggregates (ADDLs), but not Ab monomers or fibrils, could
prevent infection of PK1/2 cells when ADDLs were co-admi-
nistered with the prion inoculum. Strikingly, when added to
iPK1/2 cells already chronically infected with prions, ADDLs
had a marked cell curing effect. This protective effect appears
to be mediated by ADDL binding to PrPC. While diverse
studies have linked PrP to AD [9,11,40–43], our data raise
the possibility that soluble Ab aggregates may actually pro-
tect against prion disease. Thus, whether Ab binding to
PrPC has pathogenic or protective effects may depend on
the relative concentrations of relevant Ab and PrP assemblies.
2. Material and methods
2.1. Reagents
All chemicals and reagents were purchased from Sigma-Aldrich
unless otherwise noted. Synthetic Ab1-42 and Ab1-40 were
synthesized and purified using reversed-phase HPLC by
Dr James I. Elliott at the ERI Amyloid Laboratory (Oxford,
CT, USA). Peptide mass and purity (greater than 99%) were
confirmed by reversed-phase HPLC and electrospray/ion trap
mass spectrometry. All tissue culture reagents were obtained
from Invitrogen.
2.2. Ab preparations
Ab is prone to aggregate and can form an array of different
assemblies. In this study, we used conditions to yield prep-
arations highly enriched in: (i) monomers, (ii) pre-fibrillar
aggregates, known as ADDLs and (iii) amyloid fibrils. Mono-
meric Ab was prepared by dissolving dry Ab1–40 peptide at
2 mg ml21 in 6 M guanidine hydrochloride (GuHCl) and
then subjecting this preparation to asymmetric flow field-
flow fractionation (AFFFF). The AFFFF channel was eluted
in 50 mM ammonium bicarbonate pH 8.5, and fractions
containing monomeric Ab, as judged by molar mass
(approx. 4000 g mol21), were collected and immediately
frozen at 2808C. ADDLs were prepared essentially as
described previously [19], approximately 25 mg of Ab1–42
peptide was dissolved in anhydrous DMSO, gently rocked
for approximately 5 min and then diluted to 0.5 mg ml21 in
phenol red-free Ham’s F12 medium without L-glutamine
(Caisson Labs) and incubated quiescently at room tempera-
ture (RT). At approximately 6 h intervals, aliquots were
removed, briefly centrifuged at 16 100g and analysed using
AFFFF. Typically, at 24–36 h, less than 20% of the injected
mass eluted as monomer, as judged by the area under the
curve of both monomer and oligomer peaks. Thereafter, the
material was aliquoted and stored frozen at 2808C. To
form fibrils, Ab was solubilized and incubated as for
ADDLs, but the incubation continued for 30 days. For cell
culture experiments, Ab preparations were buffer exchanged
into Opti-MEM using a centrifugal concentrator (Amicon,
Ultra 0.5 ml, 5 K cut-off ).
2.3. Asymmetric flow field-flow fractionation and multi-
angle light scattering
Experiments were conducted using a 24.6 cm long channel
fitted with a 350 mm spacer and a 5 kDa MWCO polyether-
sulfone membrane. Aliquots of Ab preparations (190 ml)
were injected onto an Eclipse DualTec AFFFF (Wyatt Tech-
nology, Santa Barbara, CA, USA) and eluted with 50 mM
ammonium acetate pH 8.5. The sample was injected at
0.2 ml min21, followed by a 1 min focusing period, and
then eluted with a 1.5 ml min21 cross-flow for 45 min. Light
scattering was performed using a Wyatt Dawn Heleos II
multi-angle light scattering module to calculate the
molar mass.
2.4. Electron microscopy
Negative stain electron microscopy (EM) was performed as
described previously [26]. Peptide solutions (5 ml) were
loaded onto negatively charged glow-discharged copper
grids coated with a continuous carbon film. Samples were
left to adhere for 120 s and excess solution blotted with
grade 4 Whatman paper. Thereafter, grids were stained
with 2% uranyl acetate for 40 s, blotted and air-dried.
Images were acquired on an FEI Tecnai T10 electron micro-
scope operating at 100 kV and recorded on a 1 k  1 k
charge-coupled device camera (Gatan) at a typical magnifi-
cation of 34 000 with a pixel size of 5 A˚.
Prion rods were purified as described previously [4,44]
concentrated to 100 (relative to starting 10% brain hom-
ogenate) and mixed with 10 mM ADDLs and incubated at
218C for 1 h. Prion rods were pelleted by centrifugation at
16 100g and 258C for 30 min. The pellet was washed once
with Opti-MEM and centrifuged a final time. The pellet
was resuspended in Opti-MEM to one half the volume of
the starting prion/ADDL solution and stained for EM as
described above. Images were analysed for evidence of
ADDLs binding to prion rods. First, the number of protofi-
brillar and spherical Ab species in an area containing a rod
cluster were counted, then the number of Ab species in an
equivalent sized area that did not include prion rods were
counted. This was repeated for three rod clusters and three
rsob.royalsocietypublishing.org
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rod-free areas, and images were analysed by two different
users.
2.5. Automated scrapie cell assay
An automated version of the standard scrapie cell assay
(SCA) using PK1/2 cells [45] was used as described
previously [37,46]. Briefly, PK1/2 cells were grown in Opti-
MEM, containing 10% fetal calf serum; 100 U ml21 penicillin
and 100 mg ml21 streptomycin at 378C, 5% CO2. Twenty-four
hours before infection with Rocky Mountain Laboratory
(RML), PK1/2 cells were seeded in 96-well plates at 18 000
cells per well and grown in Opti-MEM. ADDLs or bovine
serum albumin (BSA) were incubated with RML prion-
infected brain homogenate (I-BH) (designated I8700; [44])
for 1 h at RT and then added to cells and incubated for
72 h. Thereafter, cells were split 1 : 8 into fresh cell culture
media containing fetal calf serum and grown to confluence.
Two further passages were conducted, removing initial
inoculum, before transferring a sample of the cells to
enzyme-linked immunospot (ELISPOT) plates for measure-
ment of the number of prion-infected cells (identified by
detection of proteinase K-resistant PrP, PrPSc), the ‘spot
count’ [45]. The viability of the cells was monitored using
Trypan Blue. Prion titre in the experimental samples was
determined by reference to a calibration curve in each exper-
iment derived from a serial dilution of an RML brain
homogenate of known prion titre (108.3 intracerebral LD50
units g21 brain) determined by prior mouse bioassay [37,44].
The ability of ADDLs to retard prion propagation was cal-
culated relative to the number of infected cells ‘spot count’ of
cells incubated with the equivalent RML concentration alone
(positive control) and the ‘spot count’ (background noise) of
cells incubated without RML present.
2.6. Curing assay of chronically Rocky Mountain
Laboratory prion-infected cells
Chronically RML prion-infected PK1/2 (designated iPK1/2)
cells were used to assay curing activity. As described pre-
viously, these cells are able to maintain a robust prion
infection long term in culture [38,39,47]. Briefly, iPK1/2
cells were produced by incubating cells with 1  1023
RML-I-BH for 72 h [44]. Thereafter, cells were passaged
every 2–3 days for 2 weeks to remove any remaining inocu-
lum. A portion of infected cells was analysed for RML prion
infectivity by ELISPOT and the remainder stored in liquid
nitrogen. For experiments, cells were thawed and cultured
as described above. In order to maintain a consistent level
of prion infection, cells were never passaged more than 15
times.
iPK1/2 cells were seeded at 6000 cells per well, in 384-
well plates. The cells were grown in Opti-MEM for 3 days
at 378C and 5% CO2+Ab. Additionally, positive (2 mM
5000 Da dextran sulfate) and negative (cells only) controls
were included on each plate. Infected cells produce PrPSc.
On day 4, cells were analysed for both viability and PrPSc
content. Cell viability was assessed using the CellTiter-Glo
Luminescent assay (Promega) and PrPSc levels were
measured by dot blot. For PrPSc analysis, the media was
removed from the cells, lysis buffer added (Tris buffer pH:
7.5 with NaCl, Triton X-100 and sodium deoxycholate) and
the cells lysed on ice for 20 min. The lysates were mixed
and bound to nitrocellulose membrane, using a 96-well bio-
dot microfiltration apparatus (BioRad). The samples were
treated with proteinase K (5 mg ml21) for 1 h at 378C and
then denatured using 3 M guanidine thiocyanate. PrPSc was
detected using the anti-PrP antibody ICSM18 (D-Gen Ltd,
London) and goat anti-mouse IgG-IRDye 800CW (LI-COR
Biosciences, Santa Clara, CA, USA). Spots were visualized
using an Odyssey infrared imaging system (LI-COR Bio-
sciences) and the relative intensity of the infrared signal
was determined using the systems software.
2.7. Immunofluorescence
PK1/2 cells were seeded at 18 000 cells per coverslip in 24-
well plates. The cells were grown in serum-free media for 3
days at 378C and 5% CO2+Ab. On day 4, coverslips were
washed three times with PBS and then fixed in 4% PFA at
RT for 15 min. After fixation, coverslips were washed twice
with PBS and then blocked with 5% BSA/PBS (1 h at RT)
and stained. Cells were incubated for 1 h at RT with the
anti-PrP antibody ICSM18 (1.25 mg ml21) and/or the
anti-Ab rabbit antiserum #2454 at 1 : 2000 dilution (Cell Sig-
nalling, Danvers, MA, USA). Thereafter, cells were washed
with PBS and then incubated with Alexa Fluor 488 tagged
donkey anti-mouse IgG (H þ L) (#A-21 202) at 2 mg ml21
and/or Alexa Fluor 546-tagged donkey anti-rabbit IgG
(H þ L) (#A10040) at 3.3 mg ml21 (Invitrogen Life Technol-
ogies). Nuclei were stained with 4,6-diamidino-2-
phenylindole, 1 mg ml21 for 1 h at RT. Cells were washed
with PBS and then mounted using fluorescence mounting
medium (DAKO). Images were captured using a Zeiss
LSM710 confocal laser scanning microscope and co-localiz-
ation quantified using VOLOCITY 3D imaging software
(Perkin Elmer).
3. Results
3.1. Ab-derived diffusible ligands inhibit prion
propagation and cure prion infection
ADDLs are a polydisperse solution of soluble Ab aggregates
which include globular oligomers, protofibrils and monomer
[11,48] and bind to the PrPC specifically and with high affi-
nity [11,13,21,26,27,29]. Two regions of PrPC (one centred
around residues 23–33 and the other around 88–113) are par-
ticularly important for Ab binding [11,13,27,29], and these
are the same sites thought to be important for PrPSc binding
to PrPc [31–36]. Thus, we sought to determine if ADDLs
could compete with prions for binding to PrPC and attenuate
prion propagation.
As ADDLs are known to bind with high affinity to PrPC,
whereas Ab monomers show little or no binding and fibrils
exhibit only weak binding [26], we generated ADDLs from
Ab42 and relatively homogeneous preparations of Ab40
monomers and Ab42 fibrils, and characterized each using
AFFFF and EM (figure 1). AFFFF is a flow-based method in
which separation takes place in a channel where sample
retention is caused by the action of a cross-flow that is gener-
ated by a second independent stream that runs across the
channel at right angles to the primary channel flow [49].
Unlike more commonly used size exclusion chromatography,
rsob.royalsocietypublishing.org
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in AFFFF, small particles elute earlier than larger particles.
AFFFF of ADDLs confirmed the presence of a small
amount of monomer and a range of Ab assemblies with
molar masses from 300 000 to 3 000 000 g mol21 (figure 1b).
EM also indicated that ADDLs contained a mixture of struc-
tures, including imperfect spheres of approximately 5–10 nm
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Figure 1. Characterization of Ab species. AFFFF is a chromatography technique in which the separation of the sample is performed in a channel rather than a
column, and separation of differently sized particles is achieved with two perpendicular flow directions of elution buffer. In AFFFF, small particles elute first, thus the
elution profile is the inverse order of size exclusion chromatography. About 190 ml of each Ab preparation was injected and eluted in 50 mM ammonium acetate
pH 8.5 at 1 ml min21. Each AFFFF plot shows absorbance at 275 nm throughout the run (blue line) and molar mass (red dots) across the main UV peak. Only the
main UV peak contained enough protein for the molar mass to be accurately calculated—see the molar mass of the buffer-only sample (d ) as an example. Data are
shown for Ab40 monomer (a), ADDLs (b), Ab42 fibrils (c) and Opti-MEM only (d ). The EM image for each sample is also shown. Scale bars: (a,b,d) 100 nm,
(c) 500 nm.
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diameter and abundant protofibrils (flexible fibrils) of
approximately 5–10 nm diameter and less than 100 nm in
length. By contrast, our monomer and fibril preparations
were relatively homogeneous. Monomer preparations had a
molar mass of 4000–5000 g mol21 (figure 1a) and contained
no structures detectable by EM, whereas fibrils had a molar
mass of greater than 109 g mol21 and formed complex lattice-
works of long fibrils with diameters of approximately 10 nm
(figure 1c).
To test if ADDLs could attenuate prion infectivity, we
used an automated high-throughput prion bioassay referred
to as the automated crapie cell assay (ASCA) [37,45,50,51].
PK1/2 cells were incubated with an RML prion-I-BH [44].
Cells were grown to confluence, split 1 : 8 and grown to con-
fluency again. The cycle of growth and passage was repeated
a further two times to remove initial infecting inoculum, and
confluent cells from the third passage were used to measure
the proportion of infected cells [37]. As expected, the extent of
prion infection is strongly influenced by the dilution of I-BH,
with lower dilutions resulting in more infected cells over the
course of the SCA (figure 2a). To determine if ADDLs could
attenuate prion infection, three dilutions of I-BH (3  1026,
1  1025, 1  1024) were incubated with a range of ADDLs
concentrations (1–10 mM) for 1 h and then added to cells
(figure 2b). The dilutions of I-BH were chosen to yield opti-
mal spot counts within the linear dynamic range of the
ELISPOT reader (see Material and methods) [37]. Impor-
tantly, addition of ADDLs to the inoculum caused a dose-
dependent decrease in the extent of prion propagation, an
effect that was directly related to the prion titre in the starting
inoculum (figure 2b). For instance, when I-BH was used at a
dilution of 3  1026 (blue curve), maximal inhibition of infec-
tivity was achieved with a dose of 5 mM ADDLs, whereas
when more concentrated I-BH (1  1024, green curve) was
used, higher concentrations of ADDLs were required to
significantly attenuate prion propagation (figure 2b). In com-
parison, addition of BSA had no effect on prion propagation
(black curve, figure 2c).
Next, we investigated if ADDLs could cure cells with an
established chronic prion infection. Chronically infected
PK1/2 cells (iPK1/2 cells) accumulate PrPSc yet remain
viable (see Material and methods) and have been successfully
used in drug screening to identify anti-prion compounds
[38,39,47]. Dextran sulfate is effective at curing prion infection
in this assay and has been used a positive control in drug
screening [39,52] and was used as a comparator to assess
the inhibitory activity of ADDLs across experiments. iPK1/
2 cells were incubated with increasing concentrations of dex-
tran sulfate for 72 h (the maximum time before the cells
require passage) and the levels of PrPSc were measured by
dot blot. As expected, dextran sulfate caused a dose-depen-
dent decrease in PrPSc with an apparent IC50 of
approximately 5  1027 M and apparent curing at concen-
trations greater than 1  1026 M (figure 3a). Incubation of
iPK1/2 cells under the same conditions, but this time in the
presence of increasing concentrations of ADDLs also resulted
in a dose-dependent reduction of PrPSc with apparent IC50
approximately 2  1025 M and apparent curing at concen-
trations greater than 5  1025 M (figure 3b). To allow
comparison between experiments, we expressed the curing
ability of ADDLs relative to the levels of PrPSc-treated cells
plus and minus 2  1026 M dextran sulfate (figure 3c). As
in the ASCA assay (figure 2), ADDLs caused a dose-
dependent decrease in the levels of PrPSc, whereas BSA did
not (figure 3c). The ability of ADDLs to cure chronic prion
infection was consistent across experiments when the same
preparation of ADDLs was used (figure 3d, preparation
C10) and when two other ADDL preparations were tested
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Figure 2. ADDLs inhibit prion propagation in the scrapie cell assay (SCA).
ADDLs were incubated with RML prions for 1 h before addition to PK1/2
cells. Every 2–3 days, the cells were split 1 : 8 and passaging was repeated
three times. After each passage, the viability and amount of infection of the
cells was assessed by trypan blue and ELISPOT revelation, respectively. (a) The
spot count of prion-infected PK1/2 cells increases with increasing concen-
tration of prion containing brain homogenate. (b) PK1/2 cells incubated
with a serial dilution of ADDLs and either 3  1026 (blue curve), 1 
1025 (red curve) or 1  1024 (green curve) diluted RML-I-BH. (c) About
3  1026 RML homogenate incubated with a serial dilution of either
ADDLs (blue curve) or BSA (black curve). ADDL concentration is based on
the monomer equivalent concentration. Data shown are the mean and stan-
dard deviation of six replicates.
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(figure 3d, preparations C12 and C14). The IC50 for ADDLs
used in six different experiments ranged from 10.4 to
22.2 mM (figure 3d ).
3.2. Ab-derived diffusible ligands, but not Ab
monomers or fibrils inhibit prion propagation
Previous studies found that Ab monomers do not bind to
PrPC and that Ab fibrils bind to PrPC less well than pre-fibril-
lar intermediates [11,26,27], hence we sought to determine if
there was a relationship between the ability of different Ab
structures to bind to PrPC and their ability to reduce prion
propagation (figure 4). First, we examined if Ab40 monomer
could influence prion propagation in the ASCA. As expected,
ADDLs caused a dose-dependent decrease in prion propa-
gation, whereas Ab monomers had no effect (figure 4a). To
determine if this prion-curing activity was similarly specific
for pre-fibrillar Ab species, we compared the effects of
ADDLs versus Ab40 monomers and Ab42 fibrils using the
chronic prion-infected cell assay. As before (figure 4b,c),
ADDLs caused a dose-dependent decrease in prion infection
(blue solid circles), whereas Ab monomers and fibrils had no
effect (figure 4b). Given that reduction in detectable PrPSc
could occur due to cell loss, and that Ab is known to be
toxic to certain cells, we were careful to measure cell viability
in all of the cultures treated with Ab. The number of
metabolically active cells (as assessed by the CellTiter-Glo
Luminescent Cell Viability assay) did not change over the
concentration range at which ADDLs inhibited prion infectiv-
ity (less than or equal to 2  1025 M; figure 4c). Therefore, the
reduction in PrPSc levels mediated by ADDLs is not a conse-
quence of cell compromise, but rather a specific effect
comparable to that seen with other prion-curing agents
[39,52,53].
3.3. Ab-derived diffusible ligands bind to the surface
of PrPC-expressing cells, but not to purified
prion rods
As both PrPC and PrPSc share the same primary structure,
including the amino acids that comprise the Ab binding
sites [27,29], we investigated whether the prion inhibition
we observed was due to Ab acting on PrPC or prions, or
both. If ADDLs inhibited infectivity by binding to prions,
then it should be possible to detect ADDLs bound to PrPSc.
To address this issue, we incubated highly purified infectious
prion rods [4,44] with ADDLs under the same conditions
used in the ASCA, and then searched for binding of
ADDLs to prions using negative stain EM (figure 5). Both
prion rods and ADDLs were readily detected, but we saw
no evidence of co-localization. This rather rudimentary
assay provides the first evidence that Ab does not bind
to PrPSc.
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Figure 3. Treatment of chronically prion-infected cells with Ab. (a) iPK1/2 cells are a subline of neuroblastoma N2a cells, which maintain a stable infection of RML
prions. Infected cells produce PrPSc without cytotoxicity. The cells were incubated with or without ADDLs for 72 h, then overall levels of PrPSc are detected by
immunoblot. (a,b) Raw luminescence units (RLUs) demonstrating the decrease in infected cells with increasing concentrations of (a) dextran sulfate or (b)
ADDLs. (c) Inhibition of PrPSc propagation by ADDLs (blue) is not seen with the same concentration of BSA (black) at concentrations between 1 and 100 mM.
Both datasets are expressed as percentage reduction in PrPSc levels relative to the reduction by 2  1026 M dextran sulfate. A reduction in PrPSc levels in
this assay correlates with reduction in prion levels assessed by bioassay. Mean and standard deviation shown, n ¼ 3. (d ) Comparison of IC50 values for three
different preparations of ADDLs in the chronically prion-infected cell assay. The mean and s.d. of n ¼ 4 for C10 is shown (n ¼ 1 for C12 and C14).
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As ADDLs did not seem to interact with prion rods, we
looked for evidence of ADDL binding to PrPC on the surface
of PK1/2 cells. Immunostaining of non-permeabilized cells
detected Ab on the surface of PK1/2 cells and partial co-
localization with PrPC (figure 6a–c). Interestingly, we also
observed that treating PK1/2 cells with ADDLs increased
cell surface levels of PrPC (figure 6b,d). In accord with earlier
reports, ADDLs appear capable of binding to PrPC [11,15]
and retaining PrPC at the plasma membrane [54]. Thus, it
seems likely that ADDLs inhibit prion levels and propagation
by competing with prions for binding to PrPC, and may also
retard internalization of PrPC.
4. Discussion
Persuasive evidence from multiple investigators argues that
certain soluble assemblies of Ab can bind tightly to PrPC
[11,13,21–23,26–29]. The interaction between PrP and soluble
Ab aggregates is highly specific [11,13,26,27,29] and involves
sites previously implicated in binding of PrPSc [31–36].
Attention has focused on how this interaction may contribute
to AD pathogenesis, but Ab binding to PrPC also has impli-
cations for prion diseases. PrPC is the obligate substrate
for prion propagation and is essential for neurotoxicity
[2,6,8,55] and agents that bind to PrPC have the potential to
modulate infectivity and toxicity [39,56].
Here, we show that ADDLs inhibit prion infectivity in a
dose-dependent manner and reduced the levels of proteinase
K-resistant PrP in chronically prion-infected cells. As both
PrPC and PrPSc have the same primary structure, including
the sites involved in ADDL binding, the ability of ADDLs
to attenuate prion propagation could result from interactions
involving either PrPC or PrPSc. When ADDLs were mixed
with highly purified prions, we found no evidence of
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Figure 4. ADDLs, Ab monomer and fibrils were tested for their ability to
cure prion infection. (a) ASCA data for the effect of Ab40 monomer
( purple) and ADDLs (blue) on RML propagation. Cells were treated with a
3  1026 dilution of RML-I-BH. Mean and s.d. of n ¼ 6 replicates
shown. (b) A reduction in PrPSc levels (corresponding to reduction in prion
titre) by Ab40 monomer ( purple), Ab42 fibrils (red) and ADDLs (blue)
using the chronically prion-infected cell assay (n ¼ 3). (c) As in (b) except
measuring cytotoxicity determined by the CellTiter-Glo Cell Viability assay.
Mean of n ¼ 2 replicates shown.
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Figure 5. ADDLs associate with PrPc on the cell surface but do not appear to
interact with PrPSc. (a) Fewer ADDLs ( p, 0.0001) are detectable in cell
media by PrP-82E1 DELFIA after 72 h when incubated with cells compared
to incubation in cell media only. Mean and s.d. of n ¼ 4 replicates
shown, univariate ANOVA. (b) Infectious RML prion rods were purified from
RML-infected mouse brain [4,44] and incubated with 10 mM ADDLs for
1 h before imaging by EM. The number of Ab oligomers was counted in
equivalent areas containing rods or without rods in three EM images of differ-
ent RML rod-Ab oligomer clusters by two different users. No enrichment of
Ab oligomers on the rods surface was observed (non-significant, p ¼ 0.456,
unpaired t-test). Scale bars, 50 nm. *p  0.05; ****p  0.0001.
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binding, whereas when ADDLs were added to PrPC-expres-
sing cells ADDLs partially co-localized with cell surface
PrPC. Moreover, as we and others have shown previously
[11,13,21,26,27], and we confirmed for preparations used in
this study (data not shown), recombinant monomeric PrP
(rPrP) readily binds ADDLs. Taken together, these data
suggest that ADDLs can attenuate prion infectivity by
directly binding to PrPC and acting as a competitive inhibitor
(electronic supplementary material, figure S1). Such a
mechanism would allow the cells’ natural prion clearance
rate [57] to outpace any residual propagation, resulting in
the low to absent levels of PrPSc observed when ADDLs
were used in our experiments. Consistent with this mechan-
ism, we also found that Ab species (monomer and fibrils)
which show little or no affinity for monomeric PrP lack the
ability to attenuate prion propagation.
The binding response between rPrP and ADDLs indicates
an apparent dissociation constant of approximately 100 nM,
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Figure 6. ADDLs and PrPc co-localize at the cell membrane and PrPc levels are increased. (a) PK1/2 cells incubated without ADDLs were immunostained with DAPI
(blue) or anti-PrP antibody ICSM18 (green) or anti-Ab antibody 2454 (red) and imaged by confocal microscopy (40 magnification). The anti-Ab antibody 2454
was included as an antibody control. (b) Immunostaining of the cells after 3 days incubation with 5 mM ADDLs show co-localization of PrPc and ADDLs at the cell
membrane. (c) About 63+ 3% of ADDLs co-localize with PrPc on the cell surface. (d ) Volocity analysis image; areas of PrP/Ab co-localization (highlighted in white)
indicated by arrows. (e) Quantification of PrPc on the cell surface of PK1/2 cells shows a significant ( p, 0.0001) increase in PrPc intensity on the surface of non-
permeabilized cells incubated with 5 mM ADDLs (62+ 6, n ¼ 14) than without ADDLs (28+ 3, n ¼ 12) (mean and s.d., two-tailed Student’s t-test).
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whereas the IC50 of ADDLs in the chronic prion-infected cell
assay was approximately 15 mM. The difference between
binding to rPrP and the ability to inhibit prion propagation
probably results because (i) ADDLs are known to bind non-
PrP membrane components [11], (ii) our assays use mitotic
cells which have a doubling time of approximately 24 h
and (iii) ADDLs are competing with prions for binding to
PrPC. In terms of ADDLs, the concentration that might be
needed to attenuate prion formation in vivo, it is worth
considering that the amount of ADDLs used in our exper-
iments are expressed as monomer equivalents, yet we know
that the component of ADDLs that binds to PrP has a rela-
tively high molecular weight and only contributes a fraction
of the total Ab present [26]. Therefore, the actual KD for the
binding component of ADDLs must be significantly lower,
and may be in the picomolar range. As to how much
ADDLs would be required to inhibit prion propagation
in vivo, that will depend on the amount of infectious prions.
Our findings are in apparent conflict with a prior study
that reported prion inoculation of Tg2576 APP transgenic
mice accelerated both Ab deposition and prion disease [58].
A possible explanation for the divergence in results seen
with Tg2576 mice and those we detected in PK1 cells relates
to the forms of Ab tested in our study and those produced by
Tg2576 mice. We and others have previously shown that only
certain forms of Ab bind to PrP [11,13] and that only particu-
lar effects of Ab are mediated by PrP [26]. Similarly, it is
known that certain APP transgenic mice exhibit cognitive
phenotypes that depend on the expression of PrP, whereas
others do not [16,25]. In terms of the acceleration of prion dis-
ease in Tg2576 mice, it is interesting to note that deleting PrPC
expression in Tg2576 results in only a partial rescue of cogni-
tive performance as opposed to the complete recovery seen in
other APP transgenic lines [59]. Further, Tg2576 mice have
been shown to produce little or no Ab species capable of
binding to PrP [59]. Given that Tg2576 mice show minimal
PrP-dependent deficits and produce little Ab that binds
PrP, it is perhaps not surprising that Tg2576 mice are
unable to attenuate prion infectivity and propagation.
Clearly, high concentrations of ADDLs should completely
inhibit prion propagation, but they are also expected to cause
neuronal dysfunction. Thus, high levels of soluble Ab assem-
blies may provide relative protection from human prion
disease, but cause AD. The lack of co-localization of dis-
ease-associated PrP and Ab deposits seen in a recent study
is of interest in this regard [60]. These observations support
the notion that soluble aggregates of Ab and PrP may com-
pete for binding to PrPC in vivo and that the balance
between the levels of these aggregates is a critical determi-
nant of whether and what form of neurodegenerative
disease will result. The most common human prion disease,
sporadic Creutzfeldt–Jakob disease, which has a relatively
uniform incidence worldwide and apparently random popu-
lation distribution, is thought to represent the spontaneous
production of prions as a rare stochastic event [61,62]. In
this regard, it has always been intriguing why its apparent
incidence falls at advanced age (greater than 80 years)
[63,64]. While this may in part be due to lower diagnosis
rates in the elderly, it is conceivable that this could also be
related to the common occurrence of Ab deposition in this
age group.
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